1 2 3 4	James Maxwell Cooper (SBN 274054) max.cooper@kirkland.com KIRKLAND & ELLIS LLP 555 California Street, 27th Floor San Francisco, California 94104-1501 Telephone: (415) 439-1400 Facsimile: (415) 439-1500	
5 6 7 8 9 10	Attorneys for Defendant ABBOTT LABORATORIES Kevin Haverty (admitted pro hac vice) khaverty@wcblegal.com WILLIAMS CUKER BEREZOFSKY, LLC 210 Lake Drive East, Suite 101 Cherry Hill, NJ 08002 Telephone: (856) 667-0500 Facsimile: (856) 667-5133 Attorney for Plaintiffs	
11 12	(Additional counsel listed on signature page)	
13	UNITED STATES DISTRICT COURT	
14	NORTHERN DISTRICT OF CALIFORNIA	
15	OAKLAND I	DIVISION
15 16	STEPHEN WENDELL AND LISA WENDELL,	DIVISION Case No: 4:09-cv-04124-CW
		Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to	Case No: 4:09-cv-04124-CW
16 17	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED,	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20 21	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE; TEVA PHARMACEUTICALS USA; GATE PHARMACEUTICALS,	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20 21 22	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE; TEVA PHARMACEUTICALS USA;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20 21 22 23	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE; TEVA PHARMACEUTICALS USA; GATE PHARMACEUTICALS, a division of TEVA PHARMACEUTICALS USA;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20 21 22 23 24	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE; TEVA PHARMACEUTICALS USA; GATE PHARMACEUTICALS, a division of TEVA PHARMACEUTICALS USA; PAR PHARMACEUTICAL, INC.;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY
16 17 18 19 20 21 22 23 24 25	STEPHEN WENDELL AND LISA WENDELL, for themselves and as successors in interest to MAXX WENDELL, DECEASED, Plaintiffs, v. JOHNSON & JOHNSON; CENTOCOR, INC.; ABBOTT LABORATORIES; SMITHKLINE BEECHAM d/b/a GLAXOSMITHKLINE; TEVA PHARMACEUTICALS USA; GATE PHARMACEUTICALS, a division of TEVA PHARMACEUTICALS USA; PAR PHARMACEUTICAL, INC.;	Case No: 4:09-cv-04124-CW STIPULATED CONFIDENTIALITY

Case No: 4:09-cv-04-124-CW

STIPULATED CONFIDENTIALITY ORDER

After good-faith negotiations, including mediation, the Plaintiffs in the above-captioned case, Defendant Abbott Laboratories, and AbbVie, Inc. have agreed to settle the above-captioned case in a Settlement Agreement. As material conditions of the Settlement Agreement, and for adequate consideration, the parties have agreed that the amount of their settlement (the "Settlement Payment" as defined in the Settlement Agreement) and other terms and conditions of their Settlement Agreement should remain confidential. Maintaining the confidentiality of the Settlement Payment and other terms and conditions of the Settlement Agreement also serves the interests of judicial administration, including the efficient resolution of the claims in this case.

Based on the foregoing, it is hereby stipulated that:

- 1. The Parties (as defined in the Settlement Agreement) and their counsel shall keep confidential and not disclose to any person (other than the Parties, and, only as reasonably necessary, their respective counsel, ethics consultants, Medicare compliance consultants, insurance carriers (including but not limited to Medicare and Medicaid), accountants, tax advisors, and financial advisors; the Court and Court employees presiding over these cases; the mediator in this case; and, to the extent necessary to obtain a good faith order from the Court, any non-settling co-defendants in the Litigation) the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, and/or any of the negotiations and discussions that preceded their making, unless otherwise specifically directed by subpoena or court order.
 - 2. This Confidentiality Order shall be attached to the Settlement Agreement.
- 3. Any communication of the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, to any person or entity other than a Party and/or their counsel shall be accompanied by a copy of this Confidentiality Order, and this Confidentiality Order shall be binding on that person or entity. Such persons or entities shall keep confidential and shall not further disclose the terms and conditions of the Settlement Agreements, including but not limited to the Settlement Payment, to any other person or entity.
- 4. In the event any Party, their counsel, or any other person or entity who has learned the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, is served with a subpoena or order that would call for the disclosure of the terms or conditions of the

Settlement Agreement, including but not limited to the Settlement Payment, such person or entity (or its counsel) shall give prompt notice to each other Party (or its respective counsel), and shall oppose disclosure until such time as the other Parties can be heard or agree to such disclosure.

- 5. If any Party, their counsel, or any other person or entity who has learned the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, believes that he/she is required by law, court order, or subpoena to disclose any terms or conditions of the Settlement Agreement, including but not limited to the Settlement Payment, such person or entity (or its counsel) shall give notice to each other Party (or its respective counsel) prior to such disclosure and, at a minimum, request that the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, be submitted to any court under seal or disclosed to any person subject to the Confidentiality Order.
- 6. Any documents filed with the Court or any other court that reference the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment, shall be filed under seal and marked as "Filed Under Seal Subject to Court's Confidentiality Order."
- 7. This Confidentiality Order shall be binding on the Parties, their counsel, and any persons or entities who learn the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment.
- 8. This Court retains jurisdiction over any disputes related to the confidentiality of the terms and conditions of the Settlement Agreement, including but not limited to the Settlement Payment. Such disputes include but are not limited to any alleged violations of this Confidentiality Order or the confidentiality provisions of the Settlement Agreement.

25

26

27

28

Case 4:09-cv-04124-CW Document 358 Filed 05/13/14 Page 4 of 5

1	DATED: May 12, 2014	Respectfully submitted,
2		/s/ James Maxwell Cooper
3		James Maxwell Cooper
4		max.cooper@kirkland.com KIRKLAND & ELLIS LLP
5		555 California Street, 27th Floor San Francisco, CA 94104
6		Telephone: (415) 439-1400 Facsimile: (415) 439-1500
7		Michael P. Foradas (pro hac vice)
8		michael.foradas@kirkland.com Renee D. Smith (pro hac vice)
9		renee.smith@kirkland.com Brenton A. Rogers (pro hac vice)
10		brenton.rogers@kirkland.com KIRKLAND & ELLIS LLP
11		300 North LaSalle Chicago, IL 60654
12		Telephone: (312) 862-2000 Facsimile: (312) 862-2200
13		Counsel for Defendant Abbott Laboratories
14	DATED 14 10 0014	/ / ***
15	DATED: May 12, 2014	<u>/s/ Kevin Haverty</u> Kevin Haverty (pro hac vice) ¹
16		khaverty@wcblegal.com WILLIAMS CUKER BEREZOFSKY, LLC
17		210 Lake Drive East, Suite 101 Cherry Hill, NJ 08002
18		Tel: 856-667-0500 Fax: 856-667-5133
19		
20	Counsel for Plaintiffs PURSUANT TO STIPULATION, IT IS SO ORDERED.	
21	TORDOM TO SHI CHAHON, II IS SO ORDERED.	
22		
23		C)
24	DATED:, 2014	CI DUCK WHI KEN
25		United States District Judge
26		
27	I, James Maxwell Cooper, hereby attest, pursuant to Local Rule 5-1(i), that concurrence in the filing of this document	
28	has been obtained from the other signatory.	

STIPULATED CONFIDENTIALITY ORDER

CERTIFICATE OF SERVICE

The undersigned hereby certifies that all counsel of record who have consented to electronic service are being served with a copy of the attached STIPULATED CONFIDENTIALITY ORDER via the CM/ECF system on May 12, 2014.

DATED: May 12, 2014 By: /s/ James Maxwell Cooper

James Maxwell Cooper max.cooper@kirkland.com KIRKLAND & ELLIS LLP 555 California Street, 27th Floor San Francisco, CA 94104-1501 Telephone: (415) 439-1400 Facsimile: (415) 439-1500

Counsel for Abbott Laboratories

Case No: 4:09-cv-04-124-CW CERTIFICATE OF SERVICE